Molecular subtyping of male breast cancer by immunohistochemistry

Robert Kornegoor, Anoek H J Verschuur-Maes, Horst Buerger, Marieke C H Hogenes, Peter C. De Bruin, Joost J. Oudejans, Petra Van Der Groep, Bernd Hinrichs, Paul J. Van Diest

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


Molecular subtyping of breast cancer by gene expression has proven its significance in females. Immunohistochemical surrogates have been used for this classification, because gene expression profiling is not yet routinely feasible. Male breast cancer is rare and large series are lacking. In this study, we used immunohistochemistry for molecular subtyping of male breast cancer. A total of 134 cases of male breast cancer were immunohistochemically stained on tissue microarrays for estrogen receptor (ER), progesterone receptor (PR), HER2 and epidermal growth factor receptor (EGFR), as well as for CK5/6, CK14, and Ki67. HER2 was also assessed by chromogen in situ hybridization. Cases were classified as luminal A (ER+ and/or PR+, and HER2-and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 driven (ER-, PR-, HER2+), basal-like (ER-, PR-, HER2-, CK5/6+ and/or CK14+ and/or EGFR), or unclassifiable triple-negative (negative for all six markers). Luminal type A was by far the most encountered type of male breast cancers, representing 75% of the cases. Luminal type B was seen in 21% and the remaining 4% of cases were classified as basal-like (n=4) and unclassifiable triple-negative (n=1). No HER2 driven cases were identified. Patients with basal-like cancer were significantly younger (P=0.034). Luminal B type cancers showed significantly higher histological grade (P

Original languageEnglish (US)
Pages (from-to)398-404
Number of pages7
JournalModern Pathology
Issue number3
StatePublished - Mar 2012
Externally publishedYes


  • breast cancer
  • immunohistochemistry
  • male
  • molecular typing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Molecular subtyping of male breast cancer by immunohistochemistry'. Together they form a unique fingerprint.

Cite this